Biliary carcinoma. A review of 109 cases.
One hundred nine patients operated on for bile duct carcinoma were reviewed. Herein, we reported 83 proximal duct tumors, 12 mid-duct tumors, and 14 distal third tumors. Resectability was 10 percent, 33 percent, and 100 percent, respectively, with an operative mortality of 0 percent, 25 percent, and 23 percent. The median survival time and 5 year survival rate for these resected groups were 21 months and 25 percent for proximal duct tumors, 8 months and 0 percent for mid-duct tumors, and 16 months and 20 percent for distal third tumors. Eighty-three patients were treated with strictly palliative procedures with an operative mortality of 19 percent, an adjusted median survival rate of 10.9 months, and a 5 year survival rate of 0. The 2 and 5 year survival rates of patients with well-differentiated tumors were 73 percent and 15 percent, respectively, whereas for patients with poorly differentiated lesions, it was 6 percent and 0. Although most patients require palliative decompressive procedures, resection should be attempted whenever possible. It is expected that nonoperative techniques will have an increased role in the treatment of poor-risk patients or those who have unresectable disease.
D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery*; D002759:Adenoma, Bile Duct / Q000401:mortality / Q000601:surgery*; D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000601:surgery*; D001652:Bile Ducts / Q000601:surgery*; D001658:Biliary Fistula / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000601:surgery*; D004386:Duodenum / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D007890:Leiomyosarcoma / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010180:Pancreatectomy; D010185:Pancreatic Fistula / Q000209:etiology; D011183:Postoperative Complications; D011379:Prognosis